266 related articles for article (PubMed ID: 20887762)
1. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC; Langer O
Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography for use in microdosing studies.
Wagner CC; Müller M; Lappin G; Langer O
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
[TBL] [Abstract][Full Text] [Related]
3. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies for microdose studies using non-radiolabeled compounds.
Maeda K; Sugiyama Y
Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
[TBL] [Abstract][Full Text] [Related]
5. Microdosing studies in humans: the role of positron emission tomography.
Bauer M; Wagner CC; Langer O
Drugs R D; 2008; 9(2):73-81. PubMed ID: 18298126
[TBL] [Abstract][Full Text] [Related]
6. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
[TBL] [Abstract][Full Text] [Related]
8. A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.
Wagner CC; Simpson M; Zeitlinger M; Bauer M; Karch R; Abrahim A; Feurstein T; Schütz M; Kletter K; Müller M; Lappin G; Langer O
Clin Pharmacokinet; 2011 Feb; 50(2):111-20. PubMed ID: 21142292
[TBL] [Abstract][Full Text] [Related]
9. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
Burt T; John CS; Ruckle JL; Vuong LT
Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
[TBL] [Abstract][Full Text] [Related]
10. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
11. The utility of microdosing over the past 5 years.
Lappin G; Garner RC
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
[TBL] [Abstract][Full Text] [Related]
12. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
13. Microdosing and drug development: past, present and future.
Lappin G; Noveck R; Burt T
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
[TBL] [Abstract][Full Text] [Related]
14. Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.
Burt T; Rouse DC; Lee K; Wu H; Layton AT; Hawk TC; Weitzel DH; Chin BB; Cohen-Wolkowiez M; Chow SC; Noveck RJ
J Nucl Med; 2015 Nov; 56(11):1793-9. PubMed ID: 26315828
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
Bergström M; Grahnén A; Långström B
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):357-66. PubMed ID: 12937873
[TBL] [Abstract][Full Text] [Related]
16. Ethical, legal, and social implications (ELSI) of microdose clinical trials.
Kurihara C
Adv Drug Deliv Rev; 2011 Jun; 63(7):503-10. PubMed ID: 21251940
[TBL] [Abstract][Full Text] [Related]
17. Impact of microdosing clinical study -- why necessary and how useful?
Sugiyama Y; Yamashita S
Adv Drug Deliv Rev; 2011 Jun; 63(7):494-502. PubMed ID: 20950660
[TBL] [Abstract][Full Text] [Related]
18. Smarter candidate selection--utilizing microdosing in exploratory clinical studies.
Buchan P
Ernst Schering Res Found Workshop; 2007; (59):7-27. PubMed ID: 17117712
[TBL] [Abstract][Full Text] [Related]
19. Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin.
Oesterreicher Z; Eberl S; Wulkersdorfer B; Matzneller P; Eder C; van Duijn E; Vaes WHJ; Reiter B; Stimpfl T; Jäger W; Nussbaumer-Proell A; Marhofer D; Marhofer P; Langer O; Zeitlinger M
Clin Pharmacokinet; 2022 May; 61(5):697-707. PubMed ID: 34997559
[TBL] [Abstract][Full Text] [Related]
20. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
Bosgra S; Vlaming ML; Vaes WH
Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
